ISSN: 2755-6328

Case Report

Open Access Journal of Pharmaceutical Sciences and Drugs

A Case-Based Review of Herb–Drug Interactions in Cancer Patients

Birbo Patra

4th Year Doctor of Pharmacy Mallige College of Pharmacy, Karnataka, India

***Corresponding author**
Birbo Patra, 4th Year Doctor of Pharmacy Mallige College of Pharmacy, Karnataka, India.

Received: August 04, 2025; **Accepted:** August 22, 2025; **Published:** August 28, 2025

ABSTRACT

Herbal medicines are widely used by cancer patients, often without clinical guidance. This case-based review explores five real-world cases where herbal supplements (Curcumin, Ashwagandha, St. John's Wort, Green Tea extract, and Giloy) significantly interacted with anticancer therapies, leading to reduced efficacy or toxicity. Each case is expanded with clear mechanistic explanations and accompanied by a summary table. The aim is to raise awareness among pharmacy students and clinicians about the clinical consequences of unsupervised herb use in oncology.

Keywords: Herb–Drug Interaction, Cancer Pharmacotherapy, Clinical Pharmacy, Pharmacovigilance, Herbal Medicine, Cytochrome P450, Patient Counseling, Pharmacist Interventions, Ayurveda, Oncology Safety

Introduction

The concurrent use of herbal medicines alongside conventional cancer treatments is an increasingly common phenomenon, especially in countries like India where traditional remedies are deeply embedded in cultural and therapeutic practices. Patients undergoing chemotherapy often turn to herbal supplements such as turmeric, ashwagandha, or green tea in hopes of boosting immunity, managing side effects, or accelerating recovery.

However, this unregulated and often undisclosed use of botanicals poses significant risks due to the potential for herb–drug interactions (HDIs), which can compromise the efficacy of chemotherapeutic agents or exacerbate toxicity.

Many herbal constituents modulate drug-metabolizing enzymes—especially the cytochrome P450 (CYP) family—or interfere with drug transporters such as P-glycoprotein.

These pharmacokinetic and pharmacodynamic interferences can lead to treatment failure, drug resistance, or increased adverse effects. Unfortunately, these risks are underreported and poorly understood by both patients and healthcare providers.

Pharmacists, with their specialized knowledge of drug mechanisms, are uniquely positioned to detect, prevent, and counsel patients regarding HDIs. This research adopts a case-based approach to analyze five real-world clinical cases involving herbal and anticancer drug interactions. The aim is to bridge the knowledge gap between traditional practices and evidence-based cancer pharmacotherapy, and to highlight the pharmacist's role in safeguarding treatment outcomes.

Objectives

1. To analyze five real-world case reports of herb–drug interactions in cancer patients using curcumin, ashwagandha, St. John's Wort, green tea, and giloy.
2. To explain the pharmacokinetic and pharmacodynamic mechanisms underlying these interactions in clear, clinically applicable language.
3. To assess the clinical outcomes and potential consequences of each interaction on cancer therapy.
4. To recommend pharmacist-centered interventions that can prevent or mitigate herb–drug interactions in oncology settings.

Citation: Birbo Patra. A Case-Based Review of Herb–Drug Interactions in Cancer Patients. Open Access J Pharma Sci and Drug. 2025. 1(2): 1-3.
DOI: doi.org/10.61440/OAJPSD.2025.v1.16

5. To promote awareness among healthcare providers and patients regarding the risks of unregulated herbal supplement use during chemotherapy.

Methodology

- **Source:** Peer-reviewed case reports from PubMed, BMJ Case Reports, Cureus, and the Indian Journal of Pharmacology.
- **Inclusion Criteria:** Published reports involving cancer patients who took herbal supplements during chemotherapy.
- **Approach:** Clinical details were extracted and mechanisms elaborated using pharmacological literature. References are clearly cited.
- **Ethical Consideration:** No patient-identifiable information used. All reports are publicly available and cited.



Case Summaries and Mechanistic Insights

Case 1: Curcumin and Tamoxifen

- **Patient:** 50-year-old female with ER+ breast cancer.
- **Interaction:** Curcumin supplement interfered with tamoxifen metabolism.
- **Mechanism:**

1. Curcumin induces CYP3A4 and CYP2D6 enzymes.
2. This increases the metabolic breakdown of tamoxifen to less active forms.
3. Leads to reduced endoxifen (active metabolite) levels.
4. Results in decreased therapeutic efficacy.

- **Outcome:** Disease progression noted within 8 months.
- **Reference:** Molecules Journal – MDPI (2019)

Case 2: Ashwagandha and Cyclophosphamide

- **Patient:** 60-year-old male with non-Hodgkin's lymphoma.
- **Interaction:** Concurrent Ashwagandha use altered chemotherapy effect.
- **Mechanism:**

1. Withaferin A in Ashwagandha activates NF-κB and modulates Hsp90.
2. Alters oxidative stress and immunological balance.
3. Reduces myelosuppression and increases hepatic stress.

- **Outcome:** Elevated liver enzymes led to delayed chemotherapy cycle.
- **Reference:** Pharmaceutics – MDPI (2022)

Case 3: St. John's Wort and Imatinib

- **Patient:** 47-year-old male with chronic myeloid leukemia (CML).
- **Interaction:** Patient self-medicated with St. John's Wort.
- **Mechanism:**

1. Hyperforin induces CYP3A4 and P-glycoprotein.
2. Accelerates metabolism and efflux of imatinib.
3. Results in reduced plasma concentration.

- **Outcome:** Molecular remission lost; drug resistance developed.
- **Reference:** Clinical Pharmacokinetics Review – Springer (2013)

Case 4: Green Tea Extract and Bortezomib

- **Patient:** 62-year-old multiple myeloma patient.
- **Interaction:** Daily EGCG (green tea catechin) blocked drug efficacy.
- **Mechanism:**

1. EGCG directly binds to the boronic acid site of bortezomib.
2. This neutralizes its proteasome inhibitory effect.
3. Tumor cells fail to undergo apoptosis.

- **Outcome:** Stable disease without desired reduction.
- **Reference:** JCO Case Reports – ASCO (2009)

Case 5: Giloy (Tinospora cordifolia) and Capecitabine

- **Patient:** 58-year-old female with colorectal cancer.
- **Interaction:** Concurrent Giloy syrup during chemotherapy.
- **Mechanism:**

1. Giloy modulates immune cytokines and may induce metabolic enzymes.
2. Possible enhancement of drug toxicity via increased oxidative stress.
3. Causes GI disturbances and liver toxicity.

- **Outcome:** Dosage had to be reduced; treatment cycle postponed.
- **Reference:** Indian Journal of Pharmacology (2021)

Summary Chart

Herb–Drug Interaction Overview

Case	Herb	Drug	Interaction Type	Mechanism Summary
1	Curcumin	Tamoxifen	CYP induction	↓ Endoxifen → Therapy failure
2	Ashwagandha	Cyclophosphamide	Immunomodulation	↑ Hepatotoxicity, ↔ Cytotoxicity
3	St. John's Wort	Imatinib	CYP/P-gp induction	↓ Drug level → Resistance
4	Green Tea (EGCG)	Bortezomib	Molecular binding inhibition	Drug neutralization → Stable disease
5	Giloy	Capecitabine	Enzyme modulation/toxicity	GI/Liver stress → Dose reduction

Conclusion

These five cases reflect the underappreciated clinical danger of herb–drug interactions in oncology. Cancer patients often use herbal remedies without disclosing them to their oncologists. Even commonly perceived "safe" herbs can compromise treatment efficacy

or exacerbate side effects. Pharmacists must actively screen for these products and educate patients on safe practices.

Pharmacist Interventions

Pharmacists play a critical role in preventing and managing herb–drug interactions, especially in oncology where the margin for error is small. To ensure patient safety and improve therapeutic outcomes, several targeted interventions should be implemented. First, pharmacists must conduct thorough medication history-taking during patient counseling sessions. This should explicitly include questions about herbal product use, as patients often do not disclose such details unless asked directly.

Secondly, the use of drug interaction-checking databases such as Lexicomp®, Micromedex®, or Stockley's Herbal Medicines Interactions is essential before dispensing medications, particularly when high-risk anticancer agents like tamoxifen, imatinib, or bortezomib are prescribed. These tools can help pharmacists identify potential interactions early and suggest safer alternatives or monitoring protocols.

Another vital step is patient education. Pharmacists should clearly communicate the risks associated with unsupervised herbal supplementation during cancer treatment. Providing printed leaflets or verbal counseling on specific interactions (e.g., curcumin reducing tamoxifen efficacy, or EGCG neutralizing bortezomib) can empower patients to make informed decisions.

Additionally, when a potential interaction is identified, pharmacists should alert the treating physician promptly and recommend evidence-based actions such as discontinuing the herb, modifying the drug dose, or enhancing monitoring. At the institutional level, pharmacists can advocate for the development of standardized protocols and checklists that flag known herb–drug risks during oncology care.

Furthermore, public health efforts led or supported by pharmacists—such as rural health campaigns or social media outreach—can increase awareness of herbal risks, particularly in areas where Ayurvedic and home remedies are widely used. Finally, pharmacists must stay current with emerging evidence by participating in continuing education programs focused on herb–drug interactions. This ensures that their clinical decisions remain rooted in the latest pharmacological science.

Through these interventions, pharmacists can serve as a vital bridge between traditional health practices and evidence-based modern medicine, safeguarding patients from unintended harms associated with herbal supplements.

Author Note

This research work was independently conducted as part of academic exploration and professional development by a fourth-year Doctor of Pharmacy (Pharm.D) student.

The author acknowledges the increasing importance of integrative medicine and the need for critical pharmacovigilance when herbal remedies are used alongside conventional cancer therapies.

No funding was received for this study. All data were obtained from publicly available, peer-reviewed case reports and scientific literature. The author affirms that every effort has been made to ensure accuracy, reliability, and academic integrity in presenting this case-based review.

This paper aims to contribute to the growing body of knowledge in clinical pharmacy by encouraging proactive pharmacist involvement in identifying, preventing, and educating patients about herb–drug interactions, particularly in oncology practice.

This research was conducted independently and is intended for educational and academic purposes only. All external sources have been properly cited and acknowledged.

References

1. Molecules Journal – MDPI (2019). https://www.mdpi.com/1420-3049/24/20/3610
2. Kashyap VK, Peasah-Darkwah G, Dhasmana A, Jaggi M, Yallapu MM, Chauhan SC. Withania somnifera: Progress towards a pharmaceutical agent for immunomodulation and cancer therapeutics. Pharmaceutics. 2022. 14: 611.
3. Clinical Pharmacokinetics Review – Springer (2013). https://link.springer.com/article/10.1007/s40262-013-0073-9
4. Journal of Clinical Oncology Case Reports – ASCO (2009). https://ascopubs.org/doi/10.1200/JCO.2009.21.7002
5. Indian Journal of Pharmacology (2021). https://www.ijp-online.com/article.asp?issn=0253- 7613;year=2021;volume=53;issue=5;spage=348;epage=351;aulast=Raut